Post-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytoma

Matar, Elie; Cook, Raymond; Fowler, Adam; Biggs, Michael T.; Little, Nicholas; Wheeler, Helen; Robinson, Bruce G.; McDonald, Kerrie L.

doi:10.1016/j.jocn.2009.12.015

Cited by 6 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Astrocytomas of higher WHO grade tend to present as more enhancing and heterogeneous lesions. However, unlike GBM, where 85 % of tumours show gadolinium enhancement on MRI [7], only 10 % of DA [101] and 29-44 % of AA [86,139] are enhancement-positive. Pallud et al [101] reported that there was no difference in overall survival (OS) regardless of the presence of contrast enhancement in grade II gliomas at initial presentation.…”

Section: Radiological Findingsmentioning

confidence: 88%

Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers

Ichimura¹,

Narita²,

Hawkins

2015

Acta Neuropathol

View full text Add to dashboard Cite

Diffusely infiltrating astrocytomas include diffuse astrocytomas WHO grade II and anaplastic astrocytomas WHO grade III and are classified under astrocytic tumours according to the current WHO Classification. Although the patients generally have longer survival as compared to those with glioblastoma, the timing of inevitable malignant progression ultimately determines the prognosis. Recent advances in molecular genetics have uncovered that histopathologically diagnosed astrocytomas may consist of two genetically different groups of tumours. The majority of diffusely infiltrating astrocytomas regardless of WHO grade have concurrent mutations of IDH1 or IDH2, TP53 and ATRX. Among these astrocytomas, no other genetic markers that may distinguish grade II and grade III tumours have been identified. Those astrocytomas without IDH mutation tend to have a distinct genotype and a poor prognosis comparable to that of glioblastomas. On the other hand, diffuse astrocytomas that arise in children do not harbour IDH/TP53 mutations, but instead display mutations of BRAF or structural alterations involving MYB/MYBL1 or FGFR1. A molecular classification may thus help delineate diffusely infiltrating astrocytomas into distinct pathogenic and prognostic groups, which could aid in determining individualised therapeutic strategies.

show abstract

Section: Radiological Findingsmentioning

confidence: 88%

Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers

Ichimura¹,

Narita²,

Hawkins

2015

Acta Neuropathol

View full text Add to dashboard Cite

show abstract

“…The leakage of the contrast agent Gd‐DTPA, which is attributed to the infiltration of tumor cells and focal abnormalities in the blood‐brain barrier, produces an increasing signal on T1‐weighted imaging. Previous studies suggested that increased neovascular permeability may also contribute to post‐CE . Furthermore, an early radiogenomic study revealed that contrast‐enhanced tumor volume was strongly associated with poor survival in glioblastoma .…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies suggested that increased neovascular permeability may also contribute to post-CE. 22 Furthermore, an early radiogenomic study revealed that contrast-enhanced tumor volume was strongly associated with poor survival in glioblastoma. 23 Hence, CE could serve as a noninvasive indicator of a tumor's biological process.…”

Section: Discussionmentioning

confidence: 99%

Molecular profiles of tumor contrast enhancement: A radiogenomic analysis in anaplastic gliomas

Liu

Sun

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

The presence of contrast enhancement (CE) on magnetic resonance (MR) imaging is conventionally regarded as an indicator for tumor malignancy. However, the biological behaviors and molecular mechanism of enhanced tumor are not well illustrated. The aim of this study was to investigate the molecular profiles associated with anaplastic gliomas (AGs) presenting CE on postcontrast T1‐weighted MR imaging. In this retrospective database study, RNA sequencing and MR imaging data of 91 AGs from the Cancer Genome Atlas (TCGA) and 64 from the Chinese Glioma Genome Atlas (CGGA) were collected. Gene set enrichment analysis (GSEA), significant analysis of microarray, generalized linear models, and Least absolute shrinkage and selection operator algorithm were used to explore radiogenomic and prognostic signatures of AG patients. GSEA indicated that angiogenesis and epithelial‐mesenchymal transition were significantly associated with post‐CE. Genes driving immune system response, cell proliferation, and focal adhesions were also significantly enriched. Gene ontology of 237 differential genes indicated consistent results. A 48‐gene signature for CE was identified in TCGA and validated in CGGA dataset (area under the curve = 0.9787). Furthermore, seven genes derived from the CE‐specific signature could stratify AG patients into two subgroups based on overall survival time according to corresponding risk score. Comprehensive analysis of post‐CE and genomic characteristics leads to a better understanding of radiology‐pathology correlations. Our gene signature helps interpret the occurrence of radiological traits and predict clinical outcomes. Additionally, we found nine prognostic quantitative radiomic features of CE and investigated the underlying biological processes of them.

show abstract

Static FET–PET and MR Imaging in Anaplastic Gliomas (WHO III)

et al. 2016

View full text Add to dashboard Cite

Post-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytoma

Cited by 6 publications

References 17 publications

Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers

Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers

Molecular profiles of tumor contrast enhancement: A radiogenomic analysis in anaplastic gliomas

Static FET–PET and MR Imaging in Anaplastic Gliomas (WHO III)

Contact Info

Product

Resources

About